Table 3.
Summary of Best Tumor Response.a
| Response (RECIST) | Response (mRECIST) | |||||
|---|---|---|---|---|---|---|
| FOLFOX-HAIC group (%) | Sorafenib group (%) | P | FOLFOX-HAIC group (%) | Sorafenib group (%) | P | |
| CR | 0 (0) | 0 (0) | - | 3 (5.5%) | 0 (0) | .11 |
| PR | 18 (32.7%) | 1 (1.7%) | <.001 | 19 (34.5%) | 2 (3.4%) | <.001 |
| SD | 26 (47.3%) | 36 (61.0%) | .14 | 22 (40.0%) | 35 (59.3%) | .04 |
| PD | 11 (20.0%) | 22 (37.3%) | .04 | 11 (20.0%) | 22 (37.3%) | .04 |
| ORR | 18 (32.7%) | 1 (1.7%) | <.001 | 22 (40.0%) | 2 (3.4%) | <.001 |
Abbreviations: FOLFOX-HAIC group, hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin group; Sorafenib group, sorafenib monotherapy group; mRECIST, modified Response Evaluation Criteria in Solid Tumors; RECIST, Response Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate.
a
Data are expressed as n (%). ORR was the proportion of patients with complete response or partial response. Statistical significance was assessed with the χ2 test.